Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Target Price at $54.33

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been assigned a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $54.33.

A number of research firms have commented on CLDX. The Goldman Sachs Group reduced their target price on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Morgan Stanley started coverage on shares of Celldex Therapeutics in a research report on Thursday, March 20th. They set an “overweight” rating and a $46.00 price target for the company. UBS Group started coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They issued a “buy” rating and a $44.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Friday, February 28th.

Institutional Investors Weigh In On Celldex Therapeutics

Several hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets lifted its stake in shares of Celldex Therapeutics by 293.2% during the third quarter. BNP Paribas Financial Markets now owns 28,181 shares of the biopharmaceutical company’s stock valued at $958,000 after buying an additional 21,013 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Celldex Therapeutics by 6.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,595 shares of the biopharmaceutical company’s stock valued at $3,487,000 after acquiring an additional 6,269 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Celldex Therapeutics by 14.5% during the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock worth $314,190,000 after purchasing an additional 1,167,659 shares during the period. XTX Topco Ltd acquired a new stake in shares of Celldex Therapeutics during the third quarter worth $1,561,000. Finally, Y Intercept Hong Kong Ltd increased its stake in Celldex Therapeutics by 11.5% in the third quarter. Y Intercept Hong Kong Ltd now owns 30,538 shares of the biopharmaceutical company’s stock valued at $1,038,000 after purchasing an additional 3,146 shares during the last quarter.

Celldex Therapeutics Stock Up 8.5 %

Shares of NASDAQ:CLDX opened at $16.41 on Monday. Celldex Therapeutics has a 52 week low of $14.40 and a 52 week high of $47.00. The company has a 50-day moving average price of $20.27 and a 200 day moving average price of $24.68. The company has a market cap of $1.09 billion, a P/E ratio of -6.39 and a beta of 1.59.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The business had revenue of $1.18 million during the quarter, compared to analysts’ expectations of $1.25 million. Analysts expect that Celldex Therapeutics will post -2.48 EPS for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.